Scribd Logo
Upload

Welcome to Scribd!

  • 35 views

    Allergan PLC.: Price, Consensus & Surprise

    Uploaded by

    derek_2010
    Allergan Plc. (NYSE:AGN) is a healthcare company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. As of August 3, 2017, AGN stock was trading at $250.36 per share. Analysts project AGN's earnings per share growth to be 25.58% for Q1 and 19.25% for fiscal year 1. AGN has a net margin of 82.42% and return on equity of 7.29%, outperforming industry averages.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Allergan PLC.: Price, Consensus & Surprise

    Uploaded by

    derek_2010
    35 views1 page
    Allergan Plc. (NYSE:AGN) is a healthcare company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. As of August 3, 2017, AGN stock was trading at $250.36 per share. Analysts project AGN's earnings per share growth to be 25.58% for Q1 and 19.25% for fiscal year 1. AGN has a net margin of 82.42% and return on equity of 7.29%, outperforming industry averages.

    Original Description:

    rpt

    Original Title

    Agn

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Allergan Plc. (NYSE:AGN) is a healthcare company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. As of August 3, 2017, AGN stock was trading at $250.36 per share. Analysts project AGN's earnings per share growth to be 25.58% for Q1 and 19.25% for fiscal year 1. AGN has a net margin of 82.42% and return on equity of 7.29%, outperforming industry averages.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    35 views1 page

    Allergan PLC.: Price, Consensus & Surprise

    Uploaded by

    derek_2010
    Allergan Plc. (NYSE:AGN) is a healthcare company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. As of August 3, 2017, AGN stock was trading at $250.36 per share. Analysts project AGN's earnings per share growth to be 25.58% for Q1 and 19.25% for fiscal year 1. AGN has a net margin of 82.42% and return on equity of 7.29%, outperforming industry averages.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 1

    August 04, 2017

    Allergan Plc. (NYSE:AGN) Zacks Rank: 3-Hold


    $250.36 USD (As of 08/03/2017) Style : Value: Growth: Momentum: VGM:

    52 Week High-Low $256.80 - $184.50 Price, Consensus & Surprise


    20 Day Average
    1,740,700
    Volume
    Beta 1.16

    Market Cap 84.09 B


    Dividend / Div Yld $2.80 / 1.12%
    Industry Medical - Generi..

    203 / 265 (Bot


    Industry Rank
    23%)
    Proj. EPS Growth (Q1) 25.58%

    Proj. EPS Growth (F1) 19.25%


    P/E (F1) 15.54
    Last EPS Surprise 1.77%

    Avg. Last 4 Surprises -0.36%


    Next Report Date 11/1/2017

    Earnings ESP 0.48%

    Agreement Estimate Revisions (60 Days) Magnitude Consensus Estimate Trend (60 Days)

    Q1 Q2 F1 F2 Q1 Q2 F1 F2

    # of Analysts 17 17 15 18 Current 4.17 4.60 16.11 18.02


    # of Revisions 4 5 3 5 7 Days Ago 4.17 4.60 16.07 18.02

    # Up 4 5 2 2 30 Days Ago 4.17 4.58 16.07 18.02

    # Down 0 0 1 3 60 Days Ago 4.17 4.57 16.09 18.09

    Trend of
    % Revision Agreement: 100% 100% 67% 60% Estimate
    Revisions: 0% +0.66% +0.12% -0.39%

    Industry Comparison Medical - Generi.. | Position in Industry: 1 of 22 Industry Peers


    AGN X Industry S&P 500 MYL TEVA RDY

    Hist. EPS Growth (3-5 yrs) 24.10% -0.77% 7.16% 18.16% -0.77% -13.67%
    Proj. Sales Growth (F1/F0) 5.32% 0.00% 5.19% 12.35% 7.22% 12.36%
    Net Margin 82.42% -17.73% 9.86% 4.59% 1.49% 7.92%
    Return on Equity 7.29% -29.88% 15.93% 23.69% 16.38% 9.40%
    Debt/Capital 25.85% 21.29% 41.65% 57.97% 47.77% 4.21%
    P/E (F1) 15.57 22.10 18.98 7.09 6.70 28.91
    Price/Sales (P/S) 5.70 3.51 2.50 1.71 1.40 2.86
    Price/Book (P/B) 1.19 2.87 3.22 1.70 0.99 3.21
    Price/Cash Flow (P/CF) 7.70 16.60 13.49 4.56 3.60 16.60
    YTD % Price Change 19.13% 1.60% 9.89% -3.22% -13.79% -18.26%

    Description Medical > Drugs > Medical - Generic Drugs


    Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and
    over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and
    other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.

    Learn More about Zacks Rank and Style Scores

    You might also like